Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Adagrasib by Bristol-Myers Squibb for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
Adagrasib by Bristol-Myers Squibb for Glioblastoma Multiforme (GBM): Likelihood of Approval
Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData,...
Adagrasib by Bristol-Myers Squibb for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to...
Adagrasib by Bristol-Myers Squibb for Solid Tumor: Likelihood of Approval
Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase III for Solid Tumor. According to GlobalData, Phase...
Adagrasib by Bristol-Myers Squibb for Colorectal Cancer: Likelihood of Approval
Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...
Adagrasib by Bristol-Myers Squibb for Breast Cancer: Likelihood of Approval
Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Breast Cancer. According to GlobalData, Phase...
Adagrasib by Bristol-Myers Squibb for Epithelial Ovarian Cancer: Likelihood of Approval
Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData,...
Adagrasib by Bristol-Myers Squibb for Uterine Cancer: Likelihood of Approval
Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase I for Uterine Cancer. According to GlobalData, Phase...
Adagrasib by Bristol-Myers Squibb for Metastatic Pancreatic Cancer: Likelihood of Approval
Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase I for Metastatic Pancreatic Cancer. According to GlobalData,...
Adagrasib by Bristol-Myers Squibb for Gynecological Cancer: Likelihood of Approval
Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase I for Gynecological Cancer. According to GlobalData, Phase...
Adagrasib by Bristol-Myers Squibb for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase III for Squamous Non-Small Cell Lung Cancer. According...
Adagrasib by Bristol-Myers Squibb for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...
Adagrasib by Bristol-Myers Squibb for Endometrial Cancer: Likelihood of Approval
Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...
Adagrasib by Bristol-Myers Squibb for Ovarian Cancer: Likelihood of Approval
Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...